MARKET

CDMO

CDMO

Avid Bioservices
NASDAQ
7.62
+0.30
+4.10%
Opening 10:33 04/26 EDT
OPEN
7.34
PREV CLOSE
7.32
HIGH
7.66
LOW
7.29
VOLUME
132.23K
TURNOVER
0
52 WEEK HIGH
19.97
52 WEEK LOW
4.071
MARKET CAP
483.72M
P/E (TTM)
-41.9604
1D
5D
1M
3M
1Y
5Y
Craig-Hallum Remains a Buy on Avid Bioservices (CDMO)
TipRanks · 1d ago
Avid Bioservices Q3 Financial Results Conference Call Announcement
TipRanks · 1d ago
Avid Bioservices misses top-line and bottom-line estimates; reaffirms FY24 outlook
Avid Bioservices misses top-line and bottom-line estimates; reaffirms FY24 outlook. The company has signed $41 million in net new business, resulting in a record high backlog of $206 million. Avid maintains revenue guidance for full fiscal year 2024 of $137 million to $147 million.
Seeking Alpha · 1d ago
CDMO Stock Earnings: Avid Bioservices Misses EPS, Beats Revenue for Q3 2024
Avid Bioservices reported earnings per share of -8 cents for the third quarter of 2024. The company reported revenue of $33.82 million. This was 1.09% better than the analyst estimate for the same period. Avid B bioservices also reported results for the second quarter.
Investorplace · 1d ago
Avid Bioservices Q3 2024 GAAP EPS $(0.09) Misses $(0.05) Estimate, Sales $33.800M Beat $33.452M Estimate
Avid Bioservices reported quarterly losses of $0.09 per share. The company reported quarterly sales of $33.800 million. This is a 11.09 percent decrease over sales of the same period last year. Avid missed the analyst consensus estimate by 80 percent.
Benzinga · 1d ago
Avid Bioservices Inc reports results for the quarter ended in January - Earnings Summary
Avid Bioservices Inc reports results for the quarter ended in January. The company reported a quarterly adjusted loss of 9 cents per share. Revenue fell 11.1% to $33.82 million from a year ago. The average analyst rating on the company's shares is "buy"
Reuters · 1d ago
*Avid Bioservices Backs FY24 Rev $137M-$147M >CDMO
Dow Jones · 1d ago
AVID BIOSERVICES OUTLOOK FY REVENUE USD 137-147 MILLION
Reuters · 1d ago
More
About CDMO
Avid Bioservices, Inc. is a contract development and manufacturing organization (CDMO). The Company provides a range of services from process development to Current Good Manufacturing Practices (CGMP) clinical and commercial manufacturing of biologics for the biotechnology and biopharmaceutical industries. It operates in a single segment, which is contract manufacturing and development services. The Company’s services include clinical and commercial product manufacturing, bulk packaging, release and stability testing and regulatory submissions support. The Company also provides a variety of process development services, including upstream and downstream development and optimization, analytical methods development, testing and characterization. It provides fully integrated and customized biomanufacturing services that support its customers from the early preclinical stage to commercial launch and supply.

Webull offers Avid Bioservices Inc stock information, including NASDAQ: CDMO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CDMO stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CDMO stock methods without spending real money on the virtual paper trading platform.